Adagene ADAG Stock
Adagene Price Chart
Adagene ADAG Financial and Trading Overview
| Adagene stock price | 3.17 USD |
| Previous Close | 3.4 USD |
| Open | 3.38 USD |
| Bid | 2.56 USD x 200 |
| Ask | 4 USD x 300 |
| Day's Range | 3.24 - 3.6 USD |
| 52 Week Range | 1.3 - 4.85 USD |
| Volume | 154.89K USD |
| Avg. Volume | 265.43K USD |
| Market Cap | 219.56M USD |
| Beta (5Y Monthly) | 0.563 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.91 USD |
ADAG Valuation Measures
| Enterprise Value | 114.29M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.839286 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 23.631805 |
| Price/Book (mrq) | 2.4549549 |
| Enterprise Value/Revenue | 12.301 |
| Enterprise Value/EBITDA | -5.206 |
Trading Information
Adagene Stock Price History
| Beta (5Y Monthly) | 0.563 |
| 52-Week Change | 54.97% |
| S&P500 52-Week Change | 15.18% |
| 52 Week High | 4.85 USD |
| 52 Week Low | 1.3 USD |
| 50-Day Moving Average | 3.73 USD |
| 200-Day Moving Average | 3.26 USD |
ADAG Share Statistics
| Avg. Volume (3 month) | 265.43K USD |
| Avg. Daily Volume (10-Days) | 164.93K USD |
| Shares Outstanding | 67.14M |
| Float | 42.2M |
| Short Ratio | 8.13 |
| % Held by Insiders | 11.36% |
| % Held by Institutions | 35.93% |
| Shares Short | 2.07M |
| Short % of Float | 3.62% |
| Short % of Shares Outstanding | 3.08% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -220.76% |
| Operating Margin (ttm) | -1023.91% |
| Gross Margin | 100.00% |
| EBITDA Margin | -236.28% |
Management Effectiveness
| Return on Assets (ttm) | -13.95% |
| Return on Equity (ttm) | -28.50% |
Income Statement
| Revenue (ttm) | 9.29M USD |
| Revenue Per Share (ttm) | 0.18 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 9.29M USD |
| EBITDA | -21952354 USD |
| Net Income Avi to Common (ttm) | -20511004 USD |
| Diluted EPS (ttm) | -0.38 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 127.91M USD |
| Total Cash Per Share (mrq) | 1.91 USD |
| Total Debt (mrq) | 6.09M USD |
| Total Debt/Equity (mrq) | 5.75 USD |
| Current Ratio (mrq) | 5.023 |
| Book Value Per Share (mrq) | 1.332 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -19247964 USD |
| Levered Free Cash Flow (ttm) | -12158853 USD |
Profile of Adagene
| Country | United States |
| State | N/A |
| City | Suzhou |
| Address | Building C14 |
| ZIP | 215123 |
| Phone | 86 512 8777 3632 |
| Website | https://www.adagene.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 128 |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Q&A For Adagene Stock
What is a current ADAG stock price?
Adagene ADAG stock price today per share is 3.17 USD.
How to purchase Adagene stock?
You can buy ADAG shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Adagene?
The stock symbol or ticker of Adagene is ADAG.
Which industry does the Adagene company belong to?
The Adagene industry is Biotechnology.
How many shares does Adagene have in circulation?
The max supply of Adagene shares is 67.14M.
What is Adagene Price to Earnings Ratio (PE Ratio)?
Adagene PE Ratio is now.
What was Adagene earnings per share over the trailing 12 months (TTM)?
Adagene EPS is -0.4 USD over the trailing 12 months.
Which sector does the Adagene company belong to?
The Adagene sector is Healthcare.
Adagene ADAG included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25978.42 USD — |
-0.01
|
9.18B USD — | 25802.96 USD — | 26225.09 USD — | — - | 9.18B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2180.51 USD — |
+0.05
|
— — | 2162.44 USD — | 2202.47 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1298.81 USD — |
+0.33
|
— — | 1291.52 USD — | 1308.69 USD — | — - | — — |
- {{ link.label }} {{link}}
